6 Life Sciences Tools & Services stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
This week, Bio-Rad Laboratories, Inc. Class A’s (BIO) ratings are up from a B last week to a A. Bio-Rad Laboratories, Inc. Class A manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components. The company also gets A’s in operating margin growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of BIO stock.
Charles River Laboratories International, Inc. (CRL) boosts its rating from a C to a B this week. Charles River Laboratories International, Inc. is a global provider of services to accelerate the drug discovery and development process. The company also gets A’s in return on equity. For more information, get Portfolio Grader’s complete analysis of CRL stock.
The rating of Luminex Corporation (LMNX) moves up this week, rising from a C to a B. Luminex Corporation develops, manufactures and markets biological testing technologies with applications throughout the clinical diagnostic and life science industries. The company also gets A’s in operating margin growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of LMNX stock.
Bruker Corporation (BRKR) is seeing ratings go up from a C last week to a B this week. Bruker Corporation designs, manufactures, markets and serves proprietary life science and materials research systems based on its core technology platforms, including X-ray technologies, magnetic resonance technologies, mass spectrometry technologies, optical emission spectroscopy and infrared and Raman molecular spectroscopy technologies. The company also gets A’s in earnings surprise and earnings momentum. For more information, get Portfolio Grader’s complete analysis of BRKR stock.
Albany Molecular Research, Inc. (AMRI) earns a B this week, jumping up from last week’s grade of C. Albany Molecular Research, Inc. provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMRI stock.
This week, Genetic Technologies Limited Sponsored ADR (GENE) pushes up from a C to a B rating. Genetic Technologies Limited Sponsored ADR is a biotechnology company that practices advanced DNA genetic research and testing. For more information, get Portfolio Grader’s complete analysis of GENE stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
